Key Highlights

  • UnitedHealth (NYSE:UNH) rose 10.24% over a month to USD 414.91 after October 13, 2026 results showed adjusted EPS of USD 4.69 and a raised outlook of at least USD 20.50, though revenue fell to USD 112.7 billion.
  • Amgen (NASDAQ:AMGN) rose 10.24% to USD 453.65 with no single October catalyst found, helped by Repatha growth of 37% in the second quarter and hopes for the MariTide obesity drug in Phase III.
  • Eli Lilly (NYSE:LLY) gained 9.91% to USD 1,297.32 after a record intraday USD 1,307.91 on October 20, 2026, and AbbVie rose 8.97% to USD 288.05 ahead of results on October 30.
  • A broad healthcare rally on October 20, 2026 reportedly took the S&P 500 Healthcare Index to a new high, lifting Lilly, Amgen, Pfizer, Johnson & Johnson and AbbVie together, so sector momentum explains much of the move.

UnitedHealth (NYSE:UNH): Up on Raised Outlook

UnitedHealth (NYSE:UNH) reported third-quarter 2026 results on October 13, 2026. Revenue was USD 112.7 billion, down from USD 113.2 billion a year earlier, while adjusted EPS rose to USD 4.69 from USD 2.92 and GAAP diluted EPS was USD 4.56. The medical care ratio, the share of premiums paid out for care, fell to 88.4% from 89.9%. The full-year outlook was raised to at least USD 20.50 of adjusted EPS and at least USD 19.50 of GAAP EPS. Chief Executive Stephen Hemsley said results reflected the discipline and execution of the teams. Published market data showed the shares closed near USD 395.62 on October 15, 2026 after a 4.7% rise. Part of the improvement came from USD 610 million of favorable prior-period reserve development. Reserve releases can recur, but they are not operating improvement. The company also said its 2027 Medicare Advantage Stars results put at least 69% of members in plans rated 4 stars or higher, in line with expectations, and it expects further commitments in 2027, without specifying them in the figures retrieved. A reserve release means the company set aside more for past claims than it needed, and the excess flows into earnings.

Amgen (NASDAQ:AMGN): Up With No Single Catalyst

No Amgen press release dated October 2026 explains the move, so this is a momentum and sector story. On October 20, 2026 the S&P 500 Healthcare Index reportedly hit a new high and Amgen rose in morning trading alongside Pfizer, Johnson & Johnson and AbbVie. Commentator Jim Cramer described the shares on October 7 as a catch-up trade after a lag against the Dow. The stock closed at USD 434.03 on October 15, up 38.6% year to date at that point, and the 10.1% single-day drop on September 8 shows how quickly sentiment can change. Since the close before the August 4 release, the shares were up 15.2% by October 15, against 1.9% for the S&P 500. Six main growth drugs grew 26% in the quarter ended June and made up nearly 70% of product sales. Repatha, a cholesterol drug, grew 37% to USD 953 million, and on August 31 Amgen reported trial evidence that Repatha reduced the risk of death in high-risk adults without a prior heart attack or stroke. Prolia and XGEVA sales fell 33% as biosimilars launched, as management had expected. MariTide, an experimental obesity drug dosed monthly or less often, is in Phase III with nine studies running and three more planned, and it generates no revenue yet.

Eli Lilly (NYSE:LLY): Up to a Record High

On October 20, 2026, Eli Lilly (NYSE:LLY) reached USD 1,307.91 intraday, up 5.45%, above its prior 52-week high of USD 1,292.65, as the S&P 500 Healthcare Index reportedly hit a new high and Amgen, Pfizer, Johnson & Johnson and AbbVie also rose. The year-to-date gain was about 21% at that point, and the stock stood at USD 1,297.32 on October 28, below the record. LSEG data showed 29 buy or strong-buy ratings, 3 holds and 1 sell, with a median target of USD 1,380.50. No Lilly press release on that day was identified, so the move reads as sector momentum on top of company strength. The monthly gain builds on the retatrutide Phase III data announced on June 8, 2026: at 12 mg, people lost about 70 pounds, or 28% of body weight, over 80 weeks, and at 4 mg about 47 pounds, or 19%, with improvements in knee pain, sleep apnea and type 2 diabetes. The obesity treatment market is cited at about USD 200 billion. Lilly also signed a drug-delivery agreement with Metis TechBio worth up to USD 1.1 billion in potential payments, and the FDA approved Onswik, a once-weekly basal insulin, on September 24, 2026, though no link to the October move was made. Investors read these data as support for pricing power.

AbbVie (NYSE:ABBV): Up Into Results

AbbVie (NYSE:ABBV) rose 8.97% over the month, but no company press release in October explains it. On October 20, 2026, AbbVie rose in morning trading alongside Eli Lilly, Amgen, Pfizer and Johnson & Johnson as the S&P 500 Healthcare Index reportedly hit a new high. On October 5, the shares were near USD 265.93, with a 50-day average of USD 257.87 and a 200-day average of USD 234.68, so the stock has risen about 8% since then, simple arithmetic on two published prices. The move therefore reflects sector momentum and steady execution. A rise of this size without company news often fades if the sector rotates, so the October 30 report matters more than usual. In the second quarter, reported on July 31, 2026, EPS of USD 3.65 compared with USD 2.97 a year earlier, and revenue of USD 16.99 billion rose 10.2%. Analysts forecast about USD 14.05 of EPS for the full year. Guidance for the third quarter was USD 3.84 to USD 3.88, while one calendar lists consensus at USD 3.73, a gap that probably reflects different adjustments, so the reported figure should be checked.

Where Things Stand

The answer is that the four gained because a sector rally on October 20, 2026 combined with company strengths. UnitedHealth (NYSE:UNH) had a raised outlook. Amgen (NASDAQ:AMGN) had Repatha growth. Eli Lilly (NYSE:LLY) had obesity-drug momentum. AbbVie (NYSE:ABBV) had steady results and reports on October 30. Only UnitedHealth had a dated October report; the others rose without a company announcement. Amgen reports on or around November 3, and Lilly's date was not retrieved.